Cynata Therapeutics Ltd
ASX:CYP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cynata Therapeutics Ltd
Accounts Payable
Cynata Therapeutics Ltd
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cynata Therapeutics Ltd
ASX:CYP
|
Accounts Payable
AU$853k
|
CAGR 3-Years
-12%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Accounts Payable
$33.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
CSL Ltd
ASX:CSL
|
Accounts Payable
$3.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Accounts Payable
AU$167.8k
|
CAGR 3-Years
-32%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Accounts Payable
AU$71.7m
|
CAGR 3-Years
62%
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Accounts Payable
AU$9.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
69%
|
CAGR 10-Years
33%
|
|
Cynata Therapeutics Ltd
Glance View
Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. The firm is engaged in the development and commercialization of a mesenchymal stem cell (MSC) technology for human therapeutic use, which the Company has branded as Cymerus. The Cymerus technology facilitates the manufacture of MSCs from a single donor and a single donation, which enables the development of therapeutic stem cell products. The firm's Cymerus platform stem cell technology is based upon stem cells known as mesenchymoangioblasts (MCAs). Its technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product. The Company’s lead product candidate, CYP-001, which has met all clinical endpoints and demonstrated safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase I trial.
See Also
What is Cynata Therapeutics Ltd's Accounts Payable?
Accounts Payable
853k
AUD
Based on the financial report for Dec 31, 2025, Cynata Therapeutics Ltd's Accounts Payable amounts to 853k AUD.
What is Cynata Therapeutics Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
2%
Over the last year, the Accounts Payable growth was -25%. The average annual Accounts Payable growth rates for Cynata Therapeutics Ltd have been -12% over the past three years , and 2% over the past ten years .
